Lazard Asset Management LLC Alnylam Pharmaceuticals, Inc. Transaction History

Lazard Asset Management LLC

$82.4 Billion
Q1 2024

A detailed history of Lazard Asset Management LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Lazard Asset Management LLC holds 3,607 shares of ALNY stock, worth $896,988. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,607

Previous 19,504 81.51%

Holding current value

$896,988

Previous $3.73 Million 85.59%

% of portfolio

0.0%

Previous 0.01%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$146.51 - $198.2 $2.33 Million - $3.15 Million	-15,897 Reduced 81.51%	3,607 $538,000
Q4 2023 Feb 14, 2024	BUY	$151.41 - $196.57 $556,128 - $722,001	3,673 Added 23.2%	19,504 $3.73 Million
Q3 2023 Nov 14, 2023	BUY	$170.77 - $211.65 $2.54 Million - $3.15 Million	14,892 Added 1585.94%	15,831 $2.8 Million
Q2 2023 Aug 14, 2023	BUY	$185.01 - $212.05 $64,753 - $74,217	350 Added 59.42%	939 $178,000
Q1 2023 May 15, 2023	BUY	$182.66 - $235.53 $18,083 - $23,317	99 Added 20.2%	589 $117,000

Q4 2022 Feb 14, 2023	SELL	$185.53 - $241.31 $11.1 Million - $14.4 Million	-59,589 Reduced 99.18%	490 $116,000
Q3 2022 Nov 14, 2022	BUY	$138.54 - $232.0 $8.22 Million - $13.8 Million	59,349 Added 8130.0%	60,079 $12 Million
Q2 2022 Aug 09, 2022	SELL	$120.42 - $169.29 $40,340 - $56,712	-335 Reduced 31.46%	730 $105,000
Q1 2022 May 13, 2022	BUY	$127.18 - $173.91 $43,495 - $59,477	342 Added 47.3%	1,065 $173,000
Q4 2021 Feb 09, 2022	SELL	$159.56 - $209.29 $165,463 - $217,033	-1,037 Reduced 58.92%	723 $122,000
Q3 2021 Nov 15, 2021	SELL	$169.75 - $207.73 $31,403 - $38,430	-185 Reduced 9.51%	1,760 $332,000
Q2 2021 Aug 12, 2021	BUY	$128.63 - $176.89 $114,480 - $157,432	890 Added 84.36%	1,945 $328,000
Q1 2021 May 14, 2021	BUY	$126.83 - $175.69 $55,678 - $77,127	439 Added 71.27%	1,055 $148,000
Q4 2020 Feb 11, 2021	BUY	$122.97 - $147.0 $2,213 - $2,646	18 Added 3.01%	616 $80,000
Q3 2020 Nov 13, 2020	SELL	$121.19 - $165.49 $321,517 - $439,044	-2,653 Reduced 81.61%	598 $87,000
Q2 2020 Aug 13, 2020	BUY	$104.21 - $156.44 $215,193 - $323,048	2,065 Added 174.11%	3,251 $481,000
Q1 2020 May 14, 2020	BUY	$93.12 - $133.99 $86,136 - $123,940	925 Added 354.41%	1,186 $129,000
Q4 2019 Feb 13, 2020	BUY	$74.51 - $124.23 $5,141 - $8,571	69 Added 35.94%	261 $30,000
Q3 2019 Nov 14, 2019	BUY	$70.9 - $87.82 $13,612 - $16,861	192 New	192 $15,000
Q3 2018 Nov 13, 2018	SELL	$87.52 - $122.67 $545,074 - $763,988	-6,228 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$115.92 - $148.54 $54,598 - $69,962	471 Added 8.18%	6,228 $741,000
Q4 2017 Feb 13, 2018	BUY	$114.49 - $139.98 $659,118 - $805,864	5,757	5,757 $730,000

Others Institutions Holding ALNY

# of Institutions

585

Shares Held

104M

Call Options Held

2.82M

Put Options Held

1.75M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.6B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.

Account

Lazard Asset Management LLC Alnylam Pharmaceuticals, Inc. Transaction History